Gapping up
In reaction to earnings/guidance:
- TUFN +17.1% (guides Q4 revenue above consensus), PRCH +10.5% (raises FY21 rev guidance; also announces four acquisitions)
Other news:
- DBVT +45.2% (receives responses from FDA pertaining to Viaskin Peanut BLA)
- AT +41.4% (to be acquired for $3.03 per share in cash)
- BB +19.1% (extends momentum from +22% gain during Thurs regular session)
- FPRX +16.5% (reports Phase 2 FIGHT trial results presented at ASCO GI that validate importance of FGFR2b overexpression and reinforce potential of bemarituzumab plus chemotherapy as a frontline targeted treatment for FGFR2b+ gastric and GEJ cancers)
- ACCD +14.1% (to acquire telemedicine start-up 2nd.MD for $460 mln)
- OII +13.3% (announces contract wins in excess of $225 mln)
- IDEX +10.3% (announces its Mobile Energy Global division's sales activities for the month of December and Q4 2020)
- CLPT +9.1% (reports first use of product in Europe)
- AAXN +8.7% (announced that the Los Angeles Police Department renewed their 5-year contract and purchased 5,260 TASER 7 energy weapons and 355 Axon Body 3 cameras) NBTX +5.3% (reports positive first results for novel NBTXR3)
- KDMN +5.1% (Point72 increases passive stake to 5.3% (prior ~3.1%))
- VBLT +5% (entered into $20 mln ordinary share purchase agreement with Aspire Capital Fund on Jan 14; Agreement extends current cash runway to Q1 2023)
- DMTK +3.3% (reports publication of positive study for its Pigmented Lesion Assay)
- KALU +2.8% (increases dividend)
- TALO +1.5% (completes refinancing and liquidity enhancing activities)
- MNR +1.3% (to explore strategic alternatives including a potential sale; also rejects previously disclosed $18/sh offer from Blackwells Capital; suspends dividend reinvestment and stock purchase plan while undergoing review)
- TEVA +1.1% (launches generic version of NuvaRing in US)
- VGR +1% (new COO)
- ADC +1% (announces inaugural monthly dividend)
Analyst comments:
- CNK +4.2% (upgraded to Buy from Neutral at B. Riley Securities)
- HPE +3% (upgraded to Overweight from Neutral at JP Morgan)
- SAH +2.4% (upgraded to Overweight from Neutral at JP Morgan)
- RL +2.3% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- SNAP +2% (upgraded to Buy from Neutral at MoffettNathanson)
- ESTC +1.6% (upgraded to Buy from Hold at Stifel)